Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
about
The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?New treatment paradigms for ADPKD: moving towards precision medicine.Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.Polycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKD.Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease
P2860
Q41998074-C3263C18-78C1-416A-99D8-E59E053C4720Q47110579-C91C16A7-93F7-4C19-B369-8250DB441D8CQ47564027-D4600D3F-44A4-4E83-B409-3E54D949CD9DQ48216298-4B87E619-64D4-42DA-9F67-DB1A2545D929Q49494721-D8CCC340-670B-49CB-84BC-7A55C4FEFFA3Q50048323-04A2E5B5-CC07-410B-9337-D86473CF93D6Q53823696-97AED326-B802-4C3B-92CD-F499BC60FA29Q54293523-1518344D-EDB5-4BFC-920A-5D14DDFADC27Q57815283-A53C476B-77CF-49D1-BD40-BE026D3515D9
P2860
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@en
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@nl
type
label
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@en
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@nl
prefLabel
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@en
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@nl
P2093
P2860
P356
P1476
Urine Osmolality, Response to ...... ults from the TEMPO 3:4 Trial.
@en
P2093
Arlene B Chapman
Eiji Higashihara
Frank S Czerwiec
Jaime D Blais
John Ouyang
Olivier Devuyst
Ron T Gansevoort
Ronald D Perrone
Vicente E Torres
P2860
P304
P356
10.1681/ASN.2016040448
P577
2016-12-05T00:00:00Z